Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Anxiolytic

or Research material

Use the filters below to narrow your results.

Other values:

None (132) · (none, never marketed) (1) · Akineton (1) · Apokyn (1) · Artane (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dostinex (1) · Eldepryl (1) · Lexotan (1) · Librium (1) · Miltown (1) · Neupro (1) · O-DSMT (1) · Ongentys (1) · Parlodel (1) · Serax (1) · Sinemet (1) · Symmetrel (1) · Tasmar (1) · Tranxene (1) · Xadago (1) · Xanax (1) · Zoloft (1)

5-HT2A agonist (26) · GABAA positive allosteric modulator (11) · Monoamine releasing agent (9) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Irreversible selective MAO-B inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (154) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (154) · 0.25 mg (1) · 25 mg (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (154) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (154) · 10 mg/d (1) · 200 mg/d (1) · N/A (never approved) (1)

None (153) · intranasal; rectal and IV reported. (1) · Oral (4) · sublingual (1)

None (153) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (153) · 6 h (immediate-release); ~11 h (extended-release) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Chronic daily dosing (1) · Long (1)

None (153) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (153) · 80-90% oral (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not formally characterized in humans. (1) · ~50% (highly variable) (1)

None (153) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)

None (154) · Rx-only (1) · Rx-only in US (1) · Schedule IV (US) (1)

Showing below up to 160 results in range #1 to #160.

1

2

3

4

5

5F-PB-22

A

B

C

D

E

F

G

GBL

H

I

Isopropylphenidate

J

K

Kava

L

M

N

O

P

R

S

T

U

U-47700

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"